Alan Maynard
Publications and Insights
- Insight: The Trump Administration’s US Drug Pricing Proposal – What will happen next?
- Insight: Advancing Rare Disease Care: Challenges and Key Issues
- Publication: The Importance of Diversity of Supply in Rare Diseases Markets
- Insight: What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
- Publication: The Cost of Drug Shortages
- Insight: Drug shortages are on the rise – but what is their impact?
- Publication: Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
- Insight: NICE at 25: HTA Methods Guidelines – Evolution, not revolution
- Publication: How Have HTA Agencies Evolved Their Methods Over Time?
- Insight: Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
- Insight: Around The World in HTAs: Türkiye – The bumpy road toward transformation
- Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
- Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
- Insight: Around The World in HTAs: The Slovak Republic – Valuing the Future
- Publication: Delivering the Triple Win: A Value-Based Approach to Pricing
- Insight: Around The World in HTAs: Spain – Are We There Yet?
- Insight: Improving the Measurement of Valued Output in Primary Care in England
- Insight: Let’s talk about (health) inequalities
- Insight: New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
- Insight: Would Waiving COVID-19 Vaccines Patents Save Lives?
- Insight: International Women’s Day: Why We #Choosetochallenge
- Insight: ‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum
- Publication: Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
- Publication: Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective
- Publication: Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
- Publication: Opportunities to Increase Efficiency in Healthcare
- Publication: A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
- Publication: Indication-Based Pricing (IBP) Consultation Report
- Publication: Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?
- Publication: Unrelieved Pain in Palliative Care in England
- Publication: The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
- Publication: Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
- Publication: Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
- Publication: Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
- Publication: The Future of Global Health Procurement: Issues around Pricing Transparency
- Publication: Making Outcome-Based Payment a Reality in the NHS
- Publication: Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
- Publication: Establishing a Reasonable Price for an Orphan Drug
- Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
- Publication: Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
- Publication: The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
- Publication: New Methods for Analysing the Distribution of EQ-5D Observations
- Publication: Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
- Publication: Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
- Publication: Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
- Publication: Why Do Immigrants Report Lower Life Satisfaction?
- Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
- Publication: Age and Utilities: Issues for HTA
- Publication: Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries
- Publication: The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics
- Publication: Uncertainty and Risk in HTA Decision Making
- Publication: The Distribution of the EQ-5D-5L Index in Patient Populations
- Publication: Four Case Studies to Explore the Added Value of Oxford AHSN
- Publication: Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
- Publication: Assessing Trends in SMC Advice Decisions (October 2009- September 2015)
- Publication: Contracting for Quality in the NHS
- Publication: A Study of the Relationship Between Health and Subjective Well-being in Parkinson’s Disease Patients
- Publication: Our Certain Fate: Rationing in Health Care
- Publication: Costs and Benefits of Regulating New Product Development in the UK Pharmaceutical Industry